FibroGen (NASDAQ:FGEN) VP Pat Cotroneo sold 42,026 shares of the business’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $52.85, for a total value of $2,221,074.10. Following the completion of the transaction, the vice president now owns 168,334 shares of the company’s stock, valued at approximately $8,896,451.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Pat Cotroneo also recently made the following trade(s):
- On Tuesday, March 13th, Pat Cotroneo sold 5,932 shares of FibroGen stock. The shares were sold at an average price of $54.61, for a total value of $323,946.52.
- On Thursday, March 8th, Pat Cotroneo sold 1,894 shares of FibroGen stock. The stock was sold at an average price of $53.12, for a total value of $100,609.28.
- On Friday, February 16th, Pat Cotroneo sold 49,500 shares of FibroGen stock. The shares were sold at an average price of $55.96, for a total value of $2,770,020.00.
- On Monday, January 22nd, Pat Cotroneo sold 25,000 shares of FibroGen stock. The shares were sold at an average price of $48.72, for a total value of $1,218,000.00.
FGEN stock traded down $0.10 during midday trading on Friday, reaching $44.90. The stock had a trading volume of 761,810 shares, compared to its average volume of 517,031. The firm has a market capitalization of $3,720.01, a price-to-earnings ratio of -25.95 and a beta of 1.89. FibroGen has a 52-week low of $24.25 and a 52-week high of $63.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.70 and a quick ratio of 9.70.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. FibroGen had a negative return on equity of 32.08% and a negative net margin of 100.43%. The firm had revenue of $42.51 million during the quarter, compared to analyst estimates of $45.37 million. equities research analysts expect that FibroGen will post -1.35 earnings per share for the current year.
A number of brokerages have issued reports on FGEN. ValuEngine upgraded FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Leerink Swann reiterated an “outperform” rating and issued a $88.00 price target (up from $80.00) on shares of FibroGen in a report on Wednesday, February 28th. Mizuho reiterated a “hold” rating and issued a $61.00 price target on shares of FibroGen in a report on Thursday, March 29th. Zacks Investment Research cut FibroGen from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. Finally, TheStreet raised FibroGen from a “d” rating to a “c-” rating in a research note on Tuesday, February 27th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $66.67.
Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in FibroGen by 4.0% in the 4th quarter. BlackRock Inc. now owns 6,326,075 shares of the biopharmaceutical company’s stock worth $299,855,000 after buying an additional 244,617 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in shares of FibroGen by 50.7% during the 4th quarter. Farallon Capital Management LLC now owns 1,657,500 shares of the biopharmaceutical company’s stock worth $78,566,000 after purchasing an additional 557,500 shares during the last quarter. Eagle Asset Management Inc. acquired a new position in shares of FibroGen during the 3rd quarter worth approximately $46,158,000. First Trust Advisors LP boosted its holdings in shares of FibroGen by 1,058.4% during the 4th quarter. First Trust Advisors LP now owns 776,640 shares of the biopharmaceutical company’s stock worth $36,813,000 after purchasing an additional 709,598 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of FibroGen by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 723,869 shares of the biopharmaceutical company’s stock worth $34,310,000 after purchasing an additional 2,312 shares during the last quarter. Hedge funds and other institutional investors own 61.39% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Pat Cotroneo Sells 42,026 Shares of FibroGen (FGEN) Stock” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/fibrogen-inc-fgen-vp-sells-2221074-10-in-stock.html.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.